How to treat functional hypogonadism

Description

Abraham Morgentaler, MD, FACS, gives an overview of functional hypogonadism, the most common causes of which are obesity and type 2 diabetes. Two patient cases are discussed.

Questions addressed in the presentation include:

Goals of testosterone therapy?

Who is a candidate for treatment?

Is there a therapeutic target level?

Do behavioral interventions help?

Treatment and monitoring

Questions addressed in the presentation include:

Goals of testosterone therapy?

Who is a candidate for treatment?

Is there a therapeutic target level?

Do behavioral interventions help?

Treatment and monitoring

Speakers

Abraham Morgentaler, MD, FACS
Past President, Androgen Society
Senior Editor, Androgens: Clinical Research And Therapeutics
Associate Professor Of Urology
Harvard Medical School

The perspective of the patients with hypogonadism

Prof. Geoff Hackett

Timely detection of hypogonadism: The importance of searching proactively

Dr. Janine David

Effects of Testosterone treatment on Type 2 Diabetes and Bone Health: Insights from the T4DM and T4Bone studies

Prof. Mathis Grossmann

ESSM 2019 Symposiums

Conferences

Access recorded conference sections presented by local and international experts